Showing results (111-120 of 142) with videos related to

Sort By:
Pageof 15
Journal of Thrombosis and Thrombolysis|July 28, 2018
Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryLarry R Jackson, Sunghee Kim, Peter Shrader, et al.
European Heart Journal|September 4, 2014
Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillationRiccardo Cappato, Michael D Ezekowitz, Allan L Klein, et al.
American Heart Journal|March 25, 2014
Physician practices regarding contraindications to oral anticoagulation in atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryEmily C O'Brien, DaJuanicia N Holmes, Jack E Ansell, et al.
European Heart Journal|February 6, 2016
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2Hans-Christoph Diener, James Aisenberg, Jack Ansell, et al.
European Heart Journal|February 6, 2016
Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1Hans-Christoph Diener, James Aisenberg, Jack Ansell, et al.
Heart (British Cardiac Society)|June 28, 2020
Patterns of oral anticoagulation use with cardioversion in clinical practiceKyle Geurink, DaJuanicia Holmes, Michael D Ezekowitz, et al.
American Heart Journal|April 29, 2014
Rationale and design of the eXplore the efficacy and safety of once-daily oral riVaroxaban for the prEvention of caRdiovascular events in patients with nonvalvular aTrial fibrillation scheduled for cardioversion trial: A comparison of oral rivaroxaban once daily with dose-adjusted vitamin K antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversionMichael D Ezekowitz, Riccardo Cappato, Allan L Klein, et al.
Lancet (London, England)|September 4, 2016
Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trialAndreas Goette, Jose L Merino, Michael D Ezekowitz, et al.
JAMA Cardiology|July 4, 2019
Association Between Warfarin Control Metrics and Atrial Fibrillation Outcomes in the Outcomes Registry for Better Informed Treatment of Atrial FibrillationSean D Pokorney, DaJuanicia N Holmes, Laine Thomas, et al.
Circulation|January 26, 2011
Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart AssociationPaul A Heidenreich, Justin G Trogdon, Olga A Khavjou, et al.
Pageof 15